Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. (NASDAQ: SNGX) Delayed: 0.39 -0.01 (2.5%)
Previous Close $0.40    52 Week High $4.35 
Open $0.40    52 Week Low $0.44 
Day High $0.41    P/E N/A 
Day Low $0.37    EPS $-0.81 
Volume 877,846